Initiation of psychotropic medication in hospitalized patients with COVID-19: Association with clinical and biological characteristics.
COVID-19
inpatient
neuropsychiatric symptoms
prescription
psychotropic medication
Journal
Human psychopharmacology
ISSN: 1099-1077
Titre abrégé: Hum Psychopharmacol
Pays: England
ID NLM: 8702539
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
19
03
2021
received:
06
03
2021
accepted:
22
03
2021
pubmed:
15
4
2021
medline:
15
9
2021
entrez:
14
4
2021
Statut:
ppublish
Résumé
Inpatients with coronavirus disease 2019 (COVID-19) show a high rate of neuropsychiatric manifestations, possibly related to a higher risk of serious illness or death. Use of psychotropic medications (PMs) indicates the presence of neuropsychiatric symptoms in COVID-19 patients. So far, potential clinical predictors of use of PMs have not been much investigated. In order to extend research in this area, we aimed to investigate the prevalence of PM prescription among a sample of inpatients with COVID-19 and to find potential predictors of initiation of PMs in these individuals. This is a cross-sectional single-center study, conducted during the first outbreak peak in a hospital of northern Italy. Information on socio-demographic characteristics, comorbidities, routine blood test, use of potential COVID-19 treatments, and length of stay were retrieved from medical records. Data were available for 151 inpatients. Forty-seven of them (31.1%) started at least one prescription of a PM. PM prescription was significantly inversely associated with lymphocyte and platelet counts. A significant association was also found for lactate dehydrogenase (LDH). Our findings suggest that the initiation of PMs could be common among COVID-19 inpatients. Lymphocyte and platelet counts as well as LDH levels may reflect neuropsychiatric complications of COVID-19.
Identifiants
pubmed: 33852168
doi: 10.1002/hup.2789
pmc: PMC8250257
doi:
Substances chimiques
Psychotropic Drugs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2789Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Biomed Pharmacother. 2021 Mar;135:111200
pubmed: 33421734
Front Aging Neurosci. 2020 Oct 26;12:588872
pubmed: 33192483
BMJ Evid Based Med. 2021 Jun;26(3):107-108
pubmed: 32934000
Brain Behav Immun. 2020 Jul;87:34-39
pubmed: 32298803
Neurol Sci. 2020 Dec;41(12):3437-3470
pubmed: 33089477
Lancet Psychiatry. 2020 Jul;7(7):611-627
pubmed: 32437679
N Engl J Med. 2020 Jun 25;382(26):2582
pubmed: 32501665
Gen Hosp Psychiatry. 2021 May-Jun;70:1-9
pubmed: 33631694
Eur Arch Psychiatry Clin Neurosci. 2020 Sep;270(6):643-644
pubmed: 32749531
Mol Neurobiol. 2021 Feb;58(2):536-549
pubmed: 32981023
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
Am J Emerg Med. 2020 Sep;38(9):1722-1726
pubmed: 32738466
Drugs R D. 2018 Mar;18(1):1-5
pubmed: 29260458
Gen Hosp Psychiatry. 2020 Nov - Dec;67:163-164
pubmed: 32636036
Clin Chim Acta. 2020 Jul;506:145-148
pubmed: 32178975
Prim Care Companion CNS Disord. 2020 May 21;22(3):
pubmed: 32441496
Hum Psychopharmacol. 2021 Sep;36(5):e2789
pubmed: 33852168
EClinicalMedicine. 2020 Sep;26:100490
pubmed: 32838241
Lancet Psychiatry. 2021 Feb;8(2):130-140
pubmed: 33181098
Crit Care. 2020 Aug 8;24(1):491
pubmed: 32771053
Ther Adv Psychopharmacol. 2020 Jul 20;10:2045125320942703
pubmed: 32733668
BMC Med. 2021 Feb 22;19(1):51
pubmed: 33612113
Lancet Psychiatry. 2020 Oct;7(10):875-882
pubmed: 32593341
Asian J Psychiatr. 2020 Oct;53:102188
pubmed: 32512530
Signal Transduct Target Ther. 2020 Mar 27;5(1):33
pubmed: 32296069
Mol Psychiatry. 2021 Sep;26(9):5199-5212
pubmed: 33536545
JAMA Netw Open. 2020 Nov 2;3(11):e2029540
pubmed: 33211114
Life Sci. 2020 Aug 1;254:117788
pubmed: 32475810
Sci Rep. 2018 Jul 12;8(1):10566
pubmed: 30002404
Eur Heart J. 2020 May 14;41(19):1821-1829
pubmed: 32383763
BMC Med. 2020 Jul 15;18(1):215
pubmed: 32664944
Asian J Psychiatr. 2020 Dec;54:102350
pubmed: 33271682